What Advanced Insulin Delivery Systems Could Mean for Type 1 Diabetes Costs and Complications

Type 1 diabetes affects around 3 million people across Europe. Even with insulin therapy, the condition can lead to serious complications: diabetic ketoacidosis (a life-threatening condition), damage to the eyes and kidneys, heart and blood vessel disease, severe low blood sugar episodes, and increased risk of early death.

These complications are expensive to treat. They create a real burden on healthcare systems and on the lives of people living with Type 1 diabetes and their families.

A new study published in *Diabetes Technology & Therapeutics* looked at how automated insulin delivery systems compare to the current standard approach: multiple daily insulin injections combined with continuous glucose monitoring that requires scanning.

Researchers built a financial model that tracked what happens over 5 years in a group of 100 people with Type 1 diabetes across nine European countries. They looked at two groups: those with harder-to-control blood sugar (HbA1c ≥8%) and those with better control (HbA1c <8%).

The findings were clear: AID systems substantially reduced the rate of serious complications compared with standard insulin injections and scanning monitors. The benefit was especially pronounced in people whose blood sugar was harder to manage.

When blood sugar control improves, fewer complications occur. That means fewer hospitalizations for diabetic ketoacidosis, fewer severe low blood sugar episodes, and reduced development of long-term damage to the eyes, kidneys, and heart.

From a healthcare perspective, preventing complications is cheaper than treating them. Better blood sugar control with advanced technology may reduce the total cost burden—even if the technology itself costs more upfront.

This research helps policymakers, healthcare systems, and insurers understand whether investing in newer insulin delivery technology makes financial sense alongside the patient benefit of fewer serious health events.

This study modeled what *could* happen based on known rates of complications and blood sugar control. Real-world results depend on many factors: how well people can access and use these systems, how well they work in different life situations, and what prices different countries actually pay.

The research assumes that better blood sugar control from AID systems leads directly to fewer complications. While the science supports this link, individual outcomes vary. Not everyone will see the same benefits, and access to these systems is not uniform across Europe or globally.

Source: Diabetes technology & therapeutics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.